JLPC(SH:600513) Zheng Quan Zhi Xing·2025-08-04 16:23Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation for the quality and efficacy of Lincomycin Hydrochloride Injection, which is expected to enhance the product's market share and competitiveness [1][3]. Drug Basic Information - Drug Name: Lincomycin Hydrochloride Injection - Dosage Form: Injection - Registration Classification: Chemical Drug - Specification: 2ml:0.6g - Original Drug Approval Number: Guoyao Zhunzi H41020229 - Drug Registration Standard Number: YBH18522025 - Acceptance Number: CYHB2450458 - Approval Conclusion: The product has passed the consistency evaluation for quality and efficacy [1]. Market Impact - The sales revenue for Lincomycin Hydrochloride Injection (2ml:0.6g) in domestic sample hospitals for 2024 is reported to be 10.82 million yuan [1]. - The successful consistency evaluation is anticipated to expand the market share of the drug, although it is noted that the approval is not expected to have a significant impact on the company's recent operating performance [3]. R&D Investment - As of the date of the announcement, the R&D investment for the consistency evaluation of Lincomycin Hydrochloride Injection by Changle Pharmaceutical is approximately in RMB [2]. - In 2025, Changle Pharmaceutical has obtained 2 production licenses [2].